Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
Idiopathic pulmonary fibrosis (IPF) is the most common type of fibrosing interstitial lung disease affecting an estimated 2.8–9.3 cases per 100,000 people per year. Onset generally occurs in the 7th decade of life. Traditional risk factors include age, male gender, tobacco use history, and family history….
Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients’ reported symptoms and expectations of the therapy.
